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2-(1-Isopropylidene and Methylbenzylidene)azino-B-n-ribo-
furanosyl-5-carbamoylmethylenethiazolidine-4-one 3 were prepared 
by acid catalyzed fusion of 2-(1-Isopropylidene and 1-Methylben-
zylidene)azino-5-carbamoylmethylenethiazolidine-(3H)-4-one 1, with 
1-0-acetyl-2,3,5-tri-O-benzoyl-B-n-ribofuranose and from deri va-
tive 7 through intermediates 9 and 10, subsequent ringclosure to 
11 and final deprotection. a and B-arabino furanosyl derivatives 
were synthesised using a direct amminolysis of protected derivative 
5. All derivatives are totally inactive against herpes simplex virus, 
while showing moderate activity against poliovirus 2. 
INTRODUCTION 
Viruses and virus-infected cells exhibit some characteristics which are 
quantitatively or qualitatively different from normal uninfected cells. It is 
now evident that quite a few specific events may occur only in virus infected 
cells and these could serve as appropriate targets for the action of antiviral 
drugs1. One of the targets, i.e. inhibition of the synthesis of viral DNA or 
RNA, was often achieved by inhibition of virus-specific DNA polymerases with 
selective antiviral agents. These agents are therefore the main synthetic aim. 
We have been involved with the synthesis of nucleoside analogues of some 
derivatives of thiazolidine acetic acids2,3 for quite some time and unfortunately 
were not able to establish possible connections between in vitro and in vivo 
biological results obtained within this series of compounds3•4 . Namely, the sugar 
component at position 3 showed a moderate enhancement in VR (virus racing) 
in comparison to the parent base, but the data were too scarce to allow any 
definite conclusions3• Nevertheless, the carboxamide group introduced on the 
exocyclic function at position 5 was considered a reasonable substituent for 
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the purpose of collecting additional data to conclude the study of the in vitro 
structure-activity relationship within this series. 
RESULTS AND DISCUSSION 
Chemistry 
The first attempt to synthesize 2-(1-isopropylidene)azino-3-B-n-ribofura-
nosyl-5-carbamoylmethylenethiazolidine-4-one 3, (R1 = R2 = CH3, R = H), fol-
lowing our previous approach3, proved to be unsuccessful due to the cleavage 
of the glycosidic bond, which suggested differences in the stability of the 
D-ribofuranosyl 3, and D-arabinofuranosyl derivatives 6. Two other possibilities 
were thus considered: 
a) glyco·sida ti on of 2-(1-isopropy lidene )azinocarbamoy lmethy lenethiazoli-
dine(3H)-4-one 1, and 
b) amminolysis of more stable derivatives prepared by modifications of 
the ribose moiety. 
a) The fusion procedure was used first2 • 2-(l-'isopropylidene)azino-5-car-
bamoylmethylenethiazolidine(3H)-4-one (1) was fused with 1-0-acetyl-2,3,5-tri-
-O-benzoyl-B-n-ribofuranose in the presence of Ii. Optimum fusion procedure 
conditions (180 °q afforded 2-(1-isopropylidene)azino-3-(2,3,5-tri-O-benzoyl-
-B-D-ribofuranosyl)-5-carbamoylmethylenethiazolidine-4-one 2, in a 30°/o 
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yield. The temperature was lowered by 20 °c and the reaction time shortened 
by 15 minutes when using the crude silylated derivative of 1, which was 
prepared by allowing 1, to react with a mixture of hexamethyldisilazane and 
trimethylchlorosilane in the ratio 10 : 1. 
This procedure afforded a sligthly improved yield (33°/o). The condensation 
of silylated derivative 1 in dry acetonitrile with 1-0-acetyl-2,3,5-tri-O-benzoyl-
-B-n-ribofuranose and SnC14 afforded an identical product; however, the yield 
was not improved. Benzoyl groups were removed with sodium methoxide 
to yield the white crystalline neucleoside 2-(1-isopropylidene)azino-3-B-n-ribo-
furanosy 1-5-carbamoy lmethy lenethi azolidine-4-one 3 (R1 = R2 = CH3). 
To prove that ribosylation took place at position 3, as well as the beta 
configuration of this nucleoside analogue, an approach based on starting ma-
terial already possesing the desired configuration has been suggested. In fact 
pathway b) corresponds to this approach, and we decided to carry out some 
additional experiments with derivatives 4 possessing a suitably protected ribose 
moiety. The reaction of 4 (R1 =R2 =CH3, R=H) with diphenylcarbonate in N,N-
-dimethylformamide as solvent and sodium hydrogen carbonate as catalyst, 
gave 2-(1-isopropylidene)azino-3-B-D-ribofuranosyl-5-methoxycarbonylmethyle-
nethiazolidine-4-one-2',3'-carbonate 7 in fair yield, together with a minor pro-
duct identified as 3',5'-carbonate 8. Derivative 7 was submitted to amminolysis 

























































































































































































































































































































































































































































































































































































































































































































































































































































































FURANOSYL DERIVATIVES 299 
obtained. Even though the five-membered cyclic carbonate ester was opened, 
the glycosidic bond remained uninterrupted, and the exocyclic methoxycarbo-
nyl group was transformed to the desired carbamoyl function. Derivative 9 
wais fused in vacuo at 160 °c to yield 2-(1-isopropylidene)azino-3-B-n-ribofura-
nosy 1-5-car bamoy lmethy lenethiazol idine-4-one-2' ,3 '-carbonate 11, which was 
readily deprotected to 3 (R1 = R 2 = CH3), identical in all respects to the product 
prepared by pathway a). It seemed that the 2',3 '-cyclic carbonate function 
stabilized the glycosidic bond, at least long enough for amminolysis of the 
ester function to be achieved in 420/o yield. It has been noticed that this 
function significantly stabilized the glysocidic bond towards acidic hydrolysdi, 
and our attempts confirmed the stability of this particular glycosidic bond in 
weakly basic conditions. 
Since both routes lead to the same product 3, the assignments of the 
anomeric configuration were correct. Additional support was provided by 13C 
NMR measurements (see Table I). The shifts observed at Cl' and C2' resonances 
correspond to the shifts which belong to the stereoisomer a-arabinofuranosyl 
derivatives 6. The indicative diminished coupling constant Jl"2. - 2.5 Hz of 
11 is conclusive as well. 
When 2-(isopropylidene)azino-3-(2,3,5-tri-O-benzyl-a and B-n-arabinofura-
nosyl)-5-methoxycarbonylmethy lenethiazolidine-4-ones 5 were treated with 
methanolic ammonia the corresponding amides 6 were isolated in fair yields, 
indicating greater stability of arabinofuranosyl derivatives 5 in comparison 
to 4. Deprotection was performed using boron trichloride at -77 °C in methy-
lene chloride, and the corresponding nucleoside analogues 6 were obtained. 
2-( 1-i,sopropy lidene )azino-a-D-arabinofur anosy 1-5-car bamoy lmethy lenethiazoli-
dine-4-one 6 was identical in all respects to the compound listed in Ref. 3, 
thus confirming the assignments of the anomeric configurations on the basis 
of 13C NMR data (see Table I) . 
Antiviral activity 
Table II presents the results of in vitro investigations of the antiviral 
activity of 2-(1-isopropylidene)azino-3-a-n-arabinofuranosyl and -B-n-ribofura-
nosyl-5-carbamoylmethylenethiazolidine-4-ones. The results indicate that a 
moderate activity against poliovirus 2 is present, in contrast to the parent 
nucleoside (R1 = R2 = CH3, R= H) where selective activity against herpes simplex 
virus was observed3• 
EXPERIMENT AL 
A) Chemistry 
Melting points were determined with a Kofler microscope and are uncorrected. 
1H-NMR spectra were obtained at 100 MHz in a Jeol PS 100 spectrometer. 13C-NMR 
spectra were determined with a JEOL FX 90Q instrument and the assignments made 
with the off resonance technique. Ultraviolet spectra were recorded with a Beckman 
Mo 25 spectrophotometer. 
Mass spectra were run in a CEC 21-llOB mass spectrometer using the FAB 
method. 
Elemental analyses were performed by Dr. Tasovac at the Ir_st;tute of Chemistry 
of the University of Natural and Mathematical Sciences, Belgrade, Yugoslavia. 
Thin layer chromatography (TLC) was performed with Merck silica gel 60 
F254 plates. Preparative chromatography was carried out with 20 x 20 plates covered 
with a 2 mm layer of Merck silica gel PF254. Merck silica gel (0.05-0.2 mm) was 
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TABLE II 




2- ( 1- Isopropy lidene) azino- 5-carbamoy lmethy lene-
thiazolidine- 4-one 1 (R1 = R2 = CHa) 
2-(1 - Isopropylidene)azino-3- B- o -ribofuranosyl-5-
-carbamoylmethylenethiazolidine- 4-one 3 
(R1=R2=CHa) 
2-( 1- Isopropy lidene )azino-3- a-o-ara binofuranosy 1-5-
-carbamoy lmethy lenethiazolidine- 4-one 6 
(R1 = R2 = CHa) 
2-(1 - Isopropy lidene )azino-3-(2' - carbamoy 1- D- ri bofura -
nosyl)-5-carbamoylmethylene-3- B-thiazolidine-4-one 9 















used for chromatographic separations. The purity of products was determined by 
thin layer chromatography on silica gel. 
Biological Screening 
All the experiments reported in this paper were performed with monolayer 
cultures of HeLa cells. Cells were maintained and propagated in Minimum Essential 
Medium supplemented with 5-100/o foetal bovine serum in a humid C02 atmosphere. 
Herpes simplex virus and poliovirus 2 were grown and assayed as previously 
described8• 
2-( 1- isopropylidene)azino -3-( 2' ,3' ,5' -tri-O-benzoyl- (J -D-ribofuranosyl) -5-
-carbamoylmethylenethiazolidine-4- one (2, R1 = R2 = CHs) 
Method A 
Dry 2-( 1-iso propy lidene )azino-5-carbamoy lmethy lenethiazolidine-(3H)-4-one ( 1) 
170 mg (0.514 mmoles) was refluxed with stirring in a mixture of hexamethyldisila-
zane and trimethylchlorosilane 10 : 1 (20 ml), 67 mg (0.5 mmoles) of ammonium 
sulphate and in the absence of moisture for 40 minutes. The excess solvent was 
removed under reduced pressure, leaving a crude silylated derivative which was 
used without further purification. 250 mg (0.5 mmoles) of dry 1-0-acetyl-2,3,5- tri-
-O-benzoyl-B-D- ribofuranose and a catalytic amount of I2 was added and the mixture 
heated with stirring in vacuo to 160 °c for 5 minutes. The residue was dissolved 
in CHCla and applied to a silica gel column (16 g) prepacked in CHCla. Elution 
was started with CHCla. The solvent was changed to CHCla- acetone of 9 : 1, and 
finally to CHC13-acetone of 9 : 3. 150 mg (33.50/o) of 2-(1 - isopropylidene)azino-3- (2',3 ',5' -
-tri- O- benzoyl-B-o-ribofuranosyl) -5- carbamoylmethylenethiazolidine-4-one (2) R1 = 
= R2 = CHa) was isolated as a syrup. 
Method B 
1 1.2 g (5.27 mmoles) and 2.5 g (4.97 mmoles) of 1- 0 -acetyl- 2,3,5-tri- O- benzoyl-
-B-o- ribofuranose with a catalytic amount of 12 was fused in vacuo at 180 °c for 
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20 minutes. The same work-up procedure yielded 950 mg (30°/o) of a product identical 
to 2 (R = C6H 5-CO) isolated by procedure A. 
Method C 
To a 150 mg (0.658 mmoles) of silylated 1, dissolved in 60 ml of dry acetonitrile, 
were added 292 mg (0.58 mmoles) of 1-0-acetyl-2,3,5-tri-O-ben zoyl-B-n-ribofuranose 
and 0.12 ml (1.03 mmoles) of SnCl4 in 10 ml acetonitrile, and the mixture refluxed 
for 2 hours; 80 ml of dichlormethane was then added to the cold reaction mixture. 
This mixture was poured into 100 ml of a saturated solution of sodium hydrogen 
carbonate. The organic layer was filtered through celite, washed several times with 
30 ml of NaCl solution and finally with water. The solution was separated, dried 
over anhydrous sodium sulphate and the solvent removed. The residue was purified 
as before, yielding 120 mg (27 O/o). 
1H -NMR (CDCla) l\<r~rs - 2.1, 2.12 (two, s, 6, C(CH3)2); 3.05 (m, 2, CH2); 4.4 (m, 1, CH) ; 
4.75 (m, 3, H4 H54); 7.5, 8.05 (m, 15, C6H5) 
Anal. C34H3209N4S calc'd: C 60.71; H 4.79; N 8.330/o 
found: C 60.20; H 4.56; N 8.030/o 
2-( 1-methylbenzylidene)azino- 3-(2' ,3' ,5' -tri-0-b enzoyl- /J -n-ribofuranosyl) - 5-carbamoyl -
meth ylenethiazolidine-4-one (2, Ri = CH3, R2 = CaH5) was obtained by method A in 
a 350/o yield. 
1H-NMR (CDC13) Bnrs - 2.52 (s, 3, CHa), 2.95 (m, 2, CH2) 
Anal. Ca9H 3409N4S calc 'd: C 63.75; H 4.66 ; N 7.630/o 
found: C 63.68; H 4.73; N 7.710/o 
2- (1 - isopropylidene)azino- 3-/J -n-ribofuranosyl- 5- carbamoylmethylenethiazolidine -4-
- one (3, Rt = R2 = CH3) 
To a solution of 2 (R1 = R2 = CH3) 0.6 g (0.96 mmoles) in 30 ml MeOH was added 
4 ml lN sodium methoxide solution. The react ion mixture was stirred at room 
temperature for 2 hours, neutralized with Dowex, filtered and the solvent removed. 
The residue was adsorbed onto silica gel (500 mg) and chromatographed on a silica 
gel column (15 g). Elution was started with CHCl:i and carried on w ith CHCla-acetone 
of 9 : 1, 7 : 3 and 1 : 1 to give 95 mg (440/o) of crystalline 2-(1-isopropylidene)azino-3-
- B- o-ribofuranosyl-5-carbamoylmethylthiazolidine-4-one (3, R1 = R2 = CHa) , m. p. 
182-184 °c. 
1H-NMR (DMSO-d6) BTMS - 1.94 (s, 6, C(CHah); 2.5 (br. m. , 2, CH2); 3.5 (br. m., 3, 
H 4" Hn ); 4.6 (m, 2, H2, NH) 5.6 (d, 1, He; Jn• = 4.5 Hz) 
UVmax (MeOH) J, = 255 nm, E = 11376 M. S: m /e = 360 (m + 1) 
Anal. C1aH2o05N4S calc'd: C 43.33; H 5.95; N 15.550/o 
found : C 43.82; H 5.72; N 15.200/o 
2-(1-methylbenzylidene)azino-3 - fJ -n-ribofuranosyl - 5-carbamoylmethylenethiazoLidine-
- 4- one (3, R=CH3, R2=CaH5) was isolated by the same procedure in a 450/o yield. 
m. p. 211-214 °c (hygroscopic) 
1H - NMR (DMSO-d6) Bnrs - 2.41 (s, 3, CH3); 2.95 (m, 2, CH2); 4.75 (m, 2, H2, NH); 
5.79 (d, 1, Hi ', J1'2 ' = 4 Hz) ; 7.45, 7.83 (m, 5, C6H5) 
UVnm: (MeOH) A= 290 nm, E = 17259 m /e = 422 (m + 1) 
Anal. C18H2206N4S·2H20 calc'd: C 47.16; H 5.72; N 12.220/o 
found: C 47.78; H 5.43; N 11.900/o 
2-(1-isopropyiidene)azino-3-fJ- n -ribofuranosyl - 5-methoxycarbonylmethylenethiazoli -
dine- 4- one -2',3'-carbonate (7, Rt=R2 =CH3) 
To a solution of 2-(isopropylidene)azino- 3- B- n- ribofuranosyl-5 -methoxycarbonyl-
methylenethiazolidine- 4-one (1.1 g, 2.93 mmoles) in N,N-dimethylformamide (2 ml) 
were added diphenylcarbonate (0.81 g, 4.45 mmoles) and a catalytic amount of sodium 
hydrogen carbonate. The reaction mixture was heated for 20 minutes at 115 °c. 
Solvent was removed at 90 °c under reduced pressure, the residue dissolved in 5 ml 
of CHCla and applied to a silica gel column (45 g) prepacked in CHC13. Elution 
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with CHCla, CHCla-acetone of 9 : 1 and finally CHCla-acetone of 8 : 2, provided 
580 mg (400/o) of 2- (1-isopropylidene)azino-3-B- o -ribofuranosyl-5-methoxycarbonyl-
methylenethiazolidine- 4- one- 2',3' -carbonate as a foam (recrystallization from MeOH 
yielded 510 mg (410/o), 7, (R1= R2=CH3) of white solid. m.p. 159-162°C). Of the 
residue, 180 mg of crude product after repeated column chromatography (8 g) and 
with CHC13-acetone of 9.5 : 0.5 gave 100 mg (120/o) of pure 3',5' -carbonate derivative 
with a m. p. of 142-145 °C. 
7, 1H-NMR (CDCla) llTMS - 2.08, 2. 11 (2s, 6, C(CHa)2); 3.15 (d, 2, CH2); 3.78 (s, 3, OCHa); 
5.45 (m, 1, Ha'); 5.81 (m, 1, H2'); 6.38 (d, 1, H1', Jn· = 3 Hz) 
UVmax (CHCla), }. = 259 nm, Ii= 12048 m / e = 401 (m + 1) 
Anal. C15H190sNaS calc'd: C 44.88; H 4.77 ; N 10.470/o 
found: C 44.37 ; H 4.91 ; N 10.370/o 
8, 'H- NMR (CDCla) DTMs -2.1 (s, 6, C(CH3)2 ; 3.12 (m, 2, CH2); 3.77 (s , 3, OCH3) ; 
5.45 (m, 1, H3'); 5.75 (dd, 1, H/); 6.52 (d, 1, H1·, Jff = 5 Hz) m /e = 401 (m + 1) 
Anal. C15H 190sN3S found: C 45.03 ; H 4.88 ; N 10.290/o 
2-(1-IsopropyLidene)azino - 3- (2' - carbamoyL and/or 3' - carbamoyL)-(1- o - ribofuranosyL - 5-
thiazoLi dine-4 - one - 2',3' -carbonate (7 , R i = CH3, R2 = CGH5) 
The same procedure provided 7 (R1 = CHa, R2 = CGHs) 
7, 1H - NMR (CDCla) llrns - 2.48 (s, 3, CHa) ; 3.14 (d, 2, CH2); 3.75 (s; 3, OCHa); 6.46 
(d, 1, H1', Jn• = 3 Hz) 
UVmax (CHCls) : Ama x= 295 nm, c: ,= 25280 
Anal. C2oH210sNaS calc'd: C 51.84; H 4.57; N 9.050/o 
found: C 51.62; H 4.63; N 9.18°,'o 
2-( 1- 1 sopropylidene)azino - 3-(2' -carbam oyL and/or 3' -carbamoy L)-B-n-ribofu ranosyL-5-
- carbamoyLmethyLenethiazoLidine - 4-one (9, 10, Ri = R2= CH.1) 
2- ( 1-isopropy lidene )azino- 3-B-o-ri bofu ranosy 1-5-methoxycarbony lmethy len ethia -
zolidine- 4- one (730 mg, 1.82 mmoles) was dissolved in methanolic ammonia (70 ml). 
The solution was kept in a pressure bottle for 90 minutes. The solvent was removed 
and the residue adsorbed onto 500 m g of silica gel. and added to a column (20 g 
prepacked in chloroform). Elution w as carried out with CHC13 and mixtures oi 
CHC13- acetone of 1 : 1, 1 : 2, 1 : 3 and finally 1 : 4. 300 mg (420/o) of a crude product, 
containing a mixture of 2- (1 -isopropylidene)azino-2'- carbamoyl and 3'-carbamoyl-
- (B-o- ribofuranosyl) - 5-carbamoylmethylenethiazolidine-4- one in crystalline form, was 
isolated with a m. p. of 178-182 °c. 
1H-NMR (D20) llDSS - 2.12, 2.20 (2s, 6, C(CHah); 3.18 (d, 2, CH2); 3.88 (m, 2, H 5, Ho"); 
5.28 (d, 1, H1', J 1'2 ' = 3 Hz) 
UVmax (MeOH) Amax= 257 nm; Ii = 11042 m /e = 404 (m + 1) 
Anal. C14H2107N5S calc'd: C 41.68; H 5.25; N 17.360/o 
found: C 41.18; H 5.35; N 17.180/o 
2- ( 1-isopropy Lidene )azino-3- (1 -o-rib ofu ranosy L- 5-ca rba may L me thy Lenethiazolidin e- 4-
- one (3 , Ri=R2=CH3) 
A catalytic amount of sodium m ethoxide in methanol was added to a solution 
of 2-(1-isopropy lidene )azino-3-B-o-ri bofuranosy 1-5-carbamoy lmethy lenethiazolidine- 4-
-one-2',3 ' - carbonate (11) (10 mg, 0.025 mmoles) in methanol \10 ml), and the resulting 
solution stirred for 1 hour. The reaction mixture was neutralized with Dowex 50 
WX8/H+, filtered and the solvent removed. 7 mg (750/o) of 2-(1-isopropylidene)azino-
- 3- B- o-ribofuranosyl- 5- carbamoylmethylenethiazolidine-4-one was obtained. The pro-
duct was identical in a ll respects to the compound 3, (R1 =R2 =CH~) isolated by the 
fusion procedure. 
2- ( 1-isopropyLidene)azino - 3- (1 -o-ribofuranosy L- 5-carbamoyLmethyLenethiazoLidine- 4-
-one-2' ,3' - carbanate (11, Ri=R2=CH3) 
2-(1-isopropy lidene )azino- 3-(2' - carbamoy 1-B- o- ri bofuranosy 1)-5-car bamoy lmethy-
l enethiazolidine-4-one (9, R1=R2 = CH3) was fused in vacuo at 160 °c until no further 
FURANOSYL DERIVATIVES 303 
release of ammonia was noticeable. The residue was dissolved in methanol, adsorbed 
on to 100 mg of silica gel and chromatographed on a silica gel column (10 g) prepacked 
in CHCla. The solut ion solvent was changed from CHCla to a mixtu re of CHCla-
-acetone of 1 : 4. 45 mg (240/o) of pure 2-(1-isopropylidene)azino-3-~-o-ribofuranosyl-
-5-carbamoylmethylenethiazolidine- 4- one- 2',3' ~carbonate was isolated as a syrup. 
1H-NMR (D20) llnss - 2.08 (s, 3, CH3); 2.15 (s, 3, CH3); 3.15 (m , 2, CH2); 3.88 (m, 2, 
H5•H5"); 6.1 (t, 1, H2•); 6.42 (d, 1, H1 •; J n • = 2.5 Hz) 
UVmax (MeOH): Amax= 257 nm, E = 12815 m /e = 386 (m + 1) 
Anal. C34H 3s05N4S calc'd: C 64.74; H 6.07; N 8.880/o 
found : C 64.73; H 5.86; N 8.660/o 
2- ( 1-isopropylidene)azino-3-(2' ,3' ,5' - tri-0-b enzyl- a- o -arabinofu ranosy!)-5-carbamoyl-
methylenethiazolidine-4-one (6, Ri=R2=CH3, R3 = benzyl) 
1H - NMR (CDC13) llnis -2.02, 2.08 (2s, 6, C(CH3)2; 2.75 (m, 2, CH2); 3.2 (m, 1, CH); 
4.5-4.8 (m, 10, H 3', H4', H 5', H5", CH2); 5.25 (dd, 1, H2'); 61.8 (d, 1, Hi'; Jn• = 6 Hz); 
7.3 (m, 15, benzyl) 
Anal. C34H3s06N4S found: C 64.76; H 6.19; N 8.790/o 
2- ( 1-methylb enzylidene )azino-3 - (2',3' ,5' -tri - 0-b enzyl-a-o-arabinofuranosyl)-5-carba-
moylmeth ylenethiazolidine-4-one (6, R 1 = CH,1, R2 = CaH5, R3 = benzyl) 
1H -NMR (CDCla) lln1s - 2.34 (s, 3, CH3j; 2.8 (m, 2, CH2); 4.2 (m, 2, Hi', CH); 4.45- 4.85 
(m, 9, H3', H5', H5", CH2); 5.3 (dd, 1, Hz'); 6.15 (d, 1, Hi ' ; Jn·= 6 Hz); 7.25 (m, 15, 
benzyl) 
Anal C39H400 6N4S calc'd: C 67.61; H 5.82; N 8.090/o 
found: C 67.70; H 5.92; N 7.890/o 
2- (1-isopropylidene)azino-a-n-arabinofuranosyl - 5-carbarnoylmethylenethiazolidine -
-4-one (6, R1=R2=CH3, Rs=H) 
A solution of 2- (1-isopropy lidene)azino-3-(2' ,3' ,5' - tri - 0 - benzyl-a-o-ara binofura-
nosyl)-5-carbamoylmethylenethiazolidine-4- one (500 mg, 0.795 mmoles) in 50 ml of 
dry methylene chloride was cooled to -77 °C. Boron. trichloride (7.36 g, 63 mmoles) 
was then added and the mixture was allowed to stand at -77 °c for 24 hours. The 
reaction mixture was then slowly dropped into a cooled (-77 °q mixture ' (70 ml) 
of methylene chloride and methanol (1 : 1) and left at -20 °c for an additional 20 
hours. Solvent was then removed at room temperature, MeOH (50 ml) was added 
to the residue, and this treatment was repeated twice. The residue was then redis-
solved in MeOH (50 ml) and neutralized with Amberlite 45. The resin was filtered 
off, washed w ith MeOH, and the filtrate evaporated to dryness. The residue was 
adsorbed onto silica gel (250 m l) and placed on top of a chromatographic column 
(6 g silica gel prepacked in CHCla). The column was eluted with CHCh, elution 
continued with a mixture of CHCla-acetone 2 : 1, 1 : 1 and finally with 3 : 7. The 
desired product was collected, and the solvent was concentrated to a small volume. 
White crystals were separated to give 90 mg (31°/o) of 2-(1-isopropylidene)azino- a-D-
-arabinofuranosyl- 5- carbamoylmethylenethiazolidine- 4- one, m. p. 198-200 °c (from 
acetone-CHCl3), identical in all respects to the compound listed in ref. 1. 
1H-NMR (D20) llnss -2.15, 2.2 (2s, 6, C(CH3)2); 3.15 (d, 2, CH2); 3.88 (m, 2, H5'H5' '); 
5.28 (dd, 1, Hz·); 6.08 (d, 1, H 1•; h2• = 7 Hz) 
UVmax (MeOH) Amax= 255 nm; E = 10296 m /e = 360 (m + 1) 
Anal. C1aH2o05N4S calc'd: C 43.33; H 5.59; N 15.590/o 
found: C 43.99; H 5.51; N 15.380/o 
2- (lmethylbenzylidene)azino-3 -a-o-arabinofuranosyl-5-carbamoylmethyelenethia-
zolidine-4- one (6) was isolated in a 230/o yield using the same procedure 
m. p. 216-218 °c (hygroscopic) 
1H-NMR (DMSO-d5) llnrs -2.52 (s, 3, CH3); 3.05 (m, 2, CH2); 5.15 (dd, 1, Hz'); 5.85 
(d, 1, Hi'; Jn• = 7 Hz); 7.55, 7.97 (m, 5, C6H 5) 
UVmax (MeOH) ),max= 725; < = 9663 m/e = 422 (m + 1) 
Anal. C1sH2205N4S·2H20 calc'd: C 47.16; H 5.72; N 12.220/o 
found: C 46.80; H 5.56; N 12.830/o 
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IZVLECEK 
Sinteza in antivirusna aktivnost 2-substituiranih azino -3-B- D-ribofuranozil in a. in 
[3-D -arabinofuranozil-5-karbamoilmetilentiazolidin-3 -onov 
J . Kobe, B. Rusjakovski in B. Brdar 
Pripravili smo 2-(1 -izopropiliden in metilbenziliden)azino-3-B- o-ribofuranozil-5-
-karbamoilmetilentiazolidin- 4-on 3 s katalizirano talilno metodo 2-(1-isopropiliden in 
1-metilbenziliden)azino-5-karbamoilmetilentiazolidin-(3H)-4-ona 1 z 1-0-acetil-2,3,5-
-tri- o-benzoil-f)-o-ri bofuranozo ter iz derivata 7 preko intermediatov 9 in 10 in 
nadaljno ciklizacijo v 11 ter octstranitvijo zascitnih skupin, a. in B arabinofuranozil 
derivate smo pripravili z direktno aminolizo zascitenih derivatov 5. Produkti kazejo 
sibko aktivnost proti poliovirusu 2, m edtem ko so neaktivni protiv virusu herpes 
simpleks. 
